Log in with your email address username.


[Correspondence] Concerns about cardiotoxicity in the HERA trial

In the HERceptin Adjuvant (HERA) trial (Feb 16, p 1195),1 the investigators reported that cardiac toxicity remained low in all groups and occurred mostly during the treatment phase. Cardiac assessments included repeated use of the New York Heart Association classification and left ventricular ejection fraction assessed by a cardiologist. However, the absence of information regarding radiation-related cardiac hazard might have caused misinterpretation of the data.